Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 338651
Licensor has technology called Liquitime that may be used for developing modified/controlled release oral pharmaceutical products in a liquid suspension formulation.
The patent is titled Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s).
The exclusive license includes Licensorâ€™s LiquiTimeÂ® Ibuprofen and LiquiTimeÂ® Guaifenesin oral suspensions; ibuprofen, an anti-inflammatory and Guaifenesin, an expectorant. These are the initial products.
IPSCIO Record ID: 319177
Licensor has developed a broad, proprietary modified-release drug delivery technology that enables the manufacture of single and multiple ingredient extended-release (XR) pharmaceuticals in patient- and caregiver-friendly orally disintegrating tablet (ODT) and oral suspension dosage forms.
Licensee is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets.
IPSCIO Record ID: 243442
The CDT system is used in solid oral dosage forms, the preferred route for drug administration. This technology is designed to produce tablets or capsules that release their active agents predictably and programmably over a specified timeframe of up to 24 hours. We believe we can apply our technology to create significant enhancements to existing pharmaceutical, OTC and nutraceutical products.
Proprietary CDT technology improves upon conventional multiple daily dose immediate release forms of existing products by providing the therapeutic benefits of controlled release drug delivery. In addition, we believe our technology can provide enhanced dosage formats for existing medications that provide superior patient convenience and product differentiation.
The technology has allowed Assignor cost-effectively develop formulations for the OTC and nutritional industries, such as glucosamine, glucosamine/chondroitin, niacin, pseudoephedrine, caffeine, vitamin C, NovasoyÂ®, and other difficult compounds and branded ingredients.
IPSCIO Record ID: 368511
Subsequent Platform Technology. with respect to the Subsequent Product, shall mean and include that certain technology that is the subject matter of US Patent Application No. 60/783,181 for Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes, and any improvements thereto whether patentable or not.
Compound shall mean morphine sulfate and/or morphine polystyrene.
Initial Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIANÂ® Referenced Product
KADIANÂ® NT shall mean the abuse deterrent form of the KADIANÂ® Reference Product which is presently the subject of Phase Ill trials being performed by or on behalf of Licensee.
Subsequent Product shall mean the pharmaceutical formulation developed under this Agreement that is demonstrated to have Bioequivalence to KADIANÂ® Referenced Product, or as to which Licensee elects to proceed hereunder without Bioequivalence) containing the Compound as its single active ingredient in a Subsequent extended-release suspension formulation with a concentration of at least 30 mg/15 ml using Licensor Subsequent Platform Technology, at one specific strength that is developed as part of the Development and Regulatory Program. In the event that the Subsequent Product is not Bioequivalent to the KADIANÂ® Referenced Product, Licensee shall have the option, but not the obligation, to proceed with the Development and Regulatory Program as if the Subsequent Product achieved Bioequivalence.
Kadian (morphine sulfate) is a narcotic pain reliever used to treat moderate to severe pain.
Licensee will gain access to Licensor's LiquiXR(TM) technology, a novel and proprietary drug delivery platform for sustained release products in liquid form. The company plans to use this technology to develop an oral liquid product complementary to the company's KADIANÂ® solid dose product line.
IPSCIO Record ID: 236350
IPSCIO Record ID: 27061
The TIMERx drug delivery system is a hydrophilic matrix combining primarily a heterodispersed mixture, usually polysaccharides xanthan and locust bean gums, in the presence of dextrose. The physical interaction between these components works to form a strong, binding gel in the presence of water. Drug release is controlled by the rate of water penetration from the gastrointestinal tract into the TIMERx gum matrix, which expands to form a gel and subsequently releases the active drug substance. The TIMERx system can precisely control the release of the active drug substance in a tablet by varying the proportion of the gums, together with the third component, the tablet coating and the tablet manufacturing process. Drugs using TIMERx technology are formulated by combining the active drug substance, the TIMERx drug delivery system and additional excipients and compressing such materials into a tablet.
1) Directly compressible sustained release excipient.
2) Sustained release excipient and tablet formulation.
3) Compressible sustained release solid dosage forms.
4) EPO Application No. 89309518.2; filed September 19, 1989.
5) Australian Patent Application No. 43057/89
6) Japanese Patent Application No. 1-510135
7) Irish Patent Application No. 2968/89
8) Canadian Patent Application No. 611,700
9) Verapamil Tablet Application, Serial No. 736,031 & EPO PCT Applications.
10) 2 U.S. Applications on Bi-modal release.
IPSCIO Record ID: 1185
Licensee desires to acquire from Licensor, and Licensor is willing to grant to Licensee, an Exclusive (as hereinafter defined) license under Licensorâ€™s Patents, Know-How and Trademarks relating to the Products in the Territory.
Product A any oral formulation product containing Budesonide or other anti-inflammatory corticosteroids as an active ingredient, formulated with a multi-matrix (MMX) drug releasing technology, for the treatment of patients with Ulcerative Colitis and all other human uses.
Product B any oral formulation product containing Rifamycin SV as an active ingredient, formulated with a multi-matrix (MMX) drug releasing technology, for the treatment of patients with Travelersâ€™ Diarrhea and all other human uses.
Budesonide MMX is an oral corticosteroid currently being investigated in two multi-center phase III clinical trials and Rifamycin SV MMX is a broad spectrum, semi-synthetic antibiotic that also has targeted release characteristics when taken orally. MMX is a proprietary technology platform designed to produce a controlled release, homogeneous local application of the active pharmaceutical ingredient throughout the colon, thereby limiting systemic absorption and offering an opportunity for reduced side effects. The MMX technology is covered by two issued U.S. patents that expire in mid-2020, and additional patent applications are pending at the U.S. Patent and Trademark Office.